Approximately 3% of the world's population has been infected with the hepat
itis C virus (HCV), which represents about 170 million chronic carriers at
risk of developing serious complications. Following the introduction of scr
eening of blood donors for infection the risk of transmitting HCV by blood
products is presently at 1/200 000 units distributed. intravenous (i.v.) dr
ug users are currently the main risk group with a prevalence rate of about
80% and a yearly incidence varying between 4 and 6%. Vertical and sexual tr
ansmissions have also been implicated but data are limited and sometimes co
ntroversial. The source of infection for the 30% of cases without an identi
fiable risk factor remains to be clarified. Prevention of spread includes d
etailed information of persons at risk of being infected, screening of high
-risk populations, strengthening of syringe exchanges among i.v. drug users
and strict application of disinfection procedures for all invasive medical
equipment.